A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Sarah A WeissDijana DjureinovicShlomit JesselIrina KrykbaevaLin ZhangLucia JilaveanuAmanda RalabateBarbara JohnsonNeta Shanwetter LevitGail AndersonDaniel ZeltermanWei WeiAmit MahajanOvid TrifanMarcus BosenbergSusan M KaechCurtis J PerryWilliam E DamskyScott GettingerMario SznolMichael HurwitzHarriet M KlugerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This first in-human study of patients with anti-PD-1/PD-L1-resistant tumors treated with dual macrophage-polarizing therapy, with or without nivolumab demonstrated safety and pharmacodynamic activity. Optimization of the dosing frequency and sequence of this combination is warranted.